The ASCO® Post, in partnership with the American Society of Clinical Oncology (ASCO), provides ASCO members, and all with an interest in oncology, access to important clinical news, summaries of timely peer-reviewed literature, and authoritative viewpoints on a variety of issues in oncology. Available in print and digitally, The ASCO® Post works to keep readers informed about the latest clinical oncology data. Under the guidance of James O. Armitage, MD, Editor-in-Chief, and past ASCO President, and a team of more than 40 editorial advisors from the United States and abroad, each issue features highly validated coverage of clinical cancer research and practice issues complemented by thoughtful commentary from leaders in the field of clinical oncology.
The ASCO® Post covers important policy issues related to value in cancer care, cost of cancer drugs, and funding for cancer research, all essential to advances in cancer care.
The ASCO® Post is the number one read oncology newspaper. Surveys indicate oncologists turn to The ASCO® Post to stay on top of important literature, data, and happenings in clinical oncology.
The ASCO® Post announces FDA approvals of novel drugs or new indications for existing oncology drug products in every issue, keeping readers up-to-date on the latest treatments.
The ASCO® Post reports on clinical data presented at oncology meetings worldwide.
In every issue, The ASCO® Post publishes "Direct From ASCO," featuring editorial content provided by ASCO and written for ASCO members. Readers learn about ASCO initiatives and opportunities, including ASCO Leadership Development opportunities, Conquer Cancer (the ASCO Foundation) the Quality Oncology Practice Initiative (QOPI) certification program, Cancer.Net, and much more.
The ASCO® Post educates readers about important trends in cancer care, including the role of immunotherapy in patient care, plus reports on targeted therapies, checkpoint inhibitors, vaccines, and more.
The ASCO® Post regularly publishes comprehensive coverage of new and updated clinical guidelines from ASCO and the National Comprehensive Cancer Network (NCCN).
In 1964, a group of seven cancer physicians banded together with a single purpose—to improve the care of people with cancer. At the time, cancer was viewed as a monolithic and frequently incurable disease, with only a handful of hard-to-tolerate and mostly ineffective therapies available. Stigma and silence left many patients with cancer with little support or information.
ASCO has held true to this vision. Over five decades, ASCO and its members have established and advanced the field of modern clinical oncology. In many ways, the story of ASCO is the story of progress against cancer. As ASCO grew from its original seven members to nearly 45,000 oncology professionals, national funding for cancer research increased from less than $200 million to more than $5 billion annually. The number of drugs available to treat cancer grew from just a handful to more than 170. And, most importantly, patients are living longer and better lives. ASCO’s members, together with patients with cancer, patient advocates, and the policymakers, government agencies, and philanthropic organizations like Conquer Cancer that have invested in vital research, have enabled and delivered these remarkable advances.
Nevertheless, cancer remains one of the world’s greatest health challenges. Prevention options are few, and many cancers are still hard to diagnose and treat. But with recent breakthroughs in technology and molecular biology, cancer care is poised to change even more dramatically in the next 20 years than over the last 50. As we look to the future, ASCO is working to harness these rapid changes in science and technology to achieve even better outcomes for tomorrow’s patients.
The ASCO Post, in partnership with the American Society of Clinical Oncology (ASCO), communicates timely and unbiased news of clinical research and updates in oncology.
Since it was launched by Harborside in 2010, The ASCO® Post has delivered timely and unbiased reports on major oncology meetings across the globe, including ASCO's Annual Meeting and regional and thematic symposia. Additionally, The ASCO® Post provides readers with important summaries of evidence-based research from peer-reviewed clinical journals (fully sourced with links to original reports); notable research, data, and literature with application in the clinic, including cost considerations/implications; and columns from ASCO's membership, with perspectives on developments in oncology, quality cancer care, technology, electronic medical records, and expert opinion on the state and economics of cancer care.
The ASCO® Post publishes news from the National Institutes of Health, the National Cancer Institute, the U.S. Food and Drug Administration, the U.S. Congress, and other governmental agencies; developments in health-care reform and the impact on oncology practice; news from the pharmaceutical and manufacturing industries; issues pertinent to community practice, careers, polls, and oncology trends; and ASCO member milestones (relocations, appointments, obituaries, etc).
News: Reports on clinical data presented at major oncology meetings in the United States and abroad—sidebars itemize key take-home messages, in an easy-to-read format. |
|
Journal Spotlight: Summaries of important, timely peer-reviewed literature with expert commentary for added perspective. Plus, coverage of important papers from the ASCO publications, Journal of Clinical Oncology (JCO) and the JCO Oncology Practice (JCO OP) are highlighted in The ASCO® Post's departments, "JCO Spotlight" and "Spotlight on JCO OP." |
|
News from the U.S. Food and Drug Administration (FDA) is included in every issue of The ASCO® Post in the departments "FDA Updates" and "In the Clinic." FDA Updates includes important news of newly approved oncology drugs and novel indications. In the Clinic examines a newly approved product in detail, explaining its indications, mechanism of action, and appropriate safety and efficacy data from pivotal trials. |
|
Clinical Trials Resource Guide includes listings of clinical studies sponsored by the National Institutes of Health and the National Cancer Institute and/or major comprehensive cancer centers. Featured studies are those that are actively recruiting patients for participation and each entry identifies the study's purpose, primary outcome measures, principal investigators, and Clinicaltrials.gov identifier. |
|
Society News: “Direct from ASCO” features info from ASCO briefings, Conquer Cancer awards, QOPI and CancerLinQ news, policy items, and more. |
|
Expert Points of View in hematology-oncology with a look at the contributions these individuals have made to improve the care of patients with cancer. |
|
Featured Op-Eds and Perspectives on important issues in hematology-oncology, including immunotherapy, precision medicine, practice guidelines, quality care, novel drugs, and more. |
|
Expert's Corner: One-on-one interviews with Key Opinion Leaders in hematology-oncology. |
*Among all Oncology Newspapers
*Among all Oncology Newspapers
*Among all Oncology Publications
*Among all Oncology Publications
Source: Kantar Media, 2021, Tables 402 & 403 Oncology and Hematology/Oncology Office and Hospital
History, Mission, and Vision:
Twenty-four issues including one annual special issue. Regular issues will be 2 ×/month for all months February-December with issue dates on the 10th and 25th of the month. Only one issue in January dated January 25th. The Narratives in Oncology Special Issue, dated June 3, 2022, will be mailed independently and also will be distributed at the ASCO Annual Meeting.
24 issue dates:
January 25 • February 10 • February 25 • March 10 • March 25 • April 10 • April 25 • May 10 • May 25 • June 3* • June 10 • June 25 • July 10 • July 25 • August 10 • August 25 • September 10 • September 25 • October 10 • October 25 • November 10 • November 25 • December 10 • December 25
*Special Issue: Narratives in Oncology
Rates effective as of January 2022. Rate changes will be issued with 90-day written notice. Fifteen percent (15%) agency discount of gross billings on space, color, cover, and preferred position charges. Payment terms are net 30 days of invoice date. Pre-payment discounts are available; contact the publisher for more information.
Earned Rates: Earned rates are given to advertisers (parent companies and their subsidiaries) based on the total number of pages placed within a 12-month period. A spread counts as two facing pages regardless of its size (king or A-size advertisement).
A subscription to The ASCO Post is sent to US-based ASCO members, including oncologists, hematologists, hematologists/oncologists, surgical oncologists, gynecologic oncologists, pediatric oncologists, and radiation oncologists, as well as all other domestic nonmember medical oncologists, hematologists, and hematologists/oncologists.
Additionally, a subscription is also available as a benefit of membership to all US-based ASCO and Advanced Practitioner Society of Hematology and Oncology (APSHO) nurse practitioners, physician assistants, and oncology pharmacists.
Breakdown by Specialty |
|
---|---|
Medical Oncology (AMA & ASCO) |
4,010 |
Hematology/Oncology (AMA & ASCO) |
11,905 |
Hematologist (AMA & ASCO) |
1,409 |
Onc & Hem/Onc (other ASCO member) |
1,400 |
Internal Medicine (ASCO) |
1,594 |
Nurse Practitioners & Physician Assistants |
1,456 |
Surgical Oncologist & Surgeon (ASCO) |
475 |
Radiation Oncologist |
742 |
Pediatric Hem/Onc (ASCO) |
582 |
Gynecologic Oncology (ASCO) |
370 |
Pathologist (ASCO) |
166 |
Oncology Pharmacist (ASCO) |
467 |
Urologist (ASCO requesters) |
128 |
Other ASCO Members* |
3,461 |
Total |
28,165 |
*Includes dermatologists, musculoskeletal oncologists, lab personnel, biostatisticians, allied health care professionals, and other field-related personnel.
U.S. Practice Location |
|
---|---|
Academic Medical Center/University |
10,398 |
Training Program |
4,237 |
Private Practice (Office or Hospital Based) |
6,504 |
Pharmaceutical/Biotech Company |
5,214 |
Administration |
649 |
Government Agency |
385 |
Staff Model HMO |
250 |
Laboratory Research |
265 |
Board Certification of US–based ASCO Members |
|
---|---|
Medical Oncology |
9,547 |
Internal Medicine |
9,159 |
Hematology |
6,117 |
Radiation Oncology |
1,141 |
Surgery (incl. Surgical Oncology) |
783 |
Other |
3,594 |
Pediatrics (incl. Pediatric Oncology) |
832 |
Gynecologic Oncology |
402 |
Oncology Pharmacy |
286 |
Oncology Nursing |
268 |
Members may choose more than one category and not all give a response—updated July 2021.
Issue Date |
News Coverage (tentative) |
Bonus Distribution at* |
---|---|---|
Jan 25th |
American Society of Hematology (ASH), San Antonio Breast Cancer Symposium (SABCS), American Society for Radiation Oncology (ASTRO), European Society for Medical Oncology (ESMO), Palliative and Supportive Care in Cancer, AACR-NCI-EORTC International Conference, Society for Immunotherapy of Cancer (SITC), ESMO Immuno-Oncology Congress, Annual Meeting of the Society of Urologic Oncology (SUO), European Colorectal Congress |
ASCO 2022 Genitourinary Cancer Symposium |
Feb 10th |
ASH, SABCS, ASTRO, ESMO |
Association of Community Cancer Centers (ACCC) |
Feb 25th |
Gastrointestinal Cancers Symposium (GI Symposium), American Association for Clinical Research Conference on Melanoma (AACR), ASH, SABCS |
Society of Surgical Oncology (SSO), Society of Gynecologic Oncology (SGO) |
Mar 10th |
GI Cancers Symposium, Genitourinary Cancers Symposium (GU Symposium) |
NCCN Annual Congress, HOPA |
Mar 25th |
ASCO-SITC Clinical Immuno-Oncology Symposium, GI Cancers Symposium, GU Cancers Symposium |
American Association for Cancer Research (AACR) |
Apr 10th |
Society of Surgical Oncology (SSO) Annual Meeting, GU Cancers Symposium, Miami Breast Cancer Conference, Multidisciplinary Thoracic Cancers Symposium, Society of Gynecologic Oncology Annual Meeting (SGO), St. Gallen International Breast Cancer Conference, NCCN Annual Conference |
Oncology Nursing Society Congress |
Apr 25th |
AACR Annual Meeting, NCCN Annual Conference, St. Gallen International Breast Cancer Conference, SGO, Miami Breast Cancer Conference, Annual Symposium on Pancreatic Cancer, Association of Community Cancer Centers (ACCC) |
|
May 10th |
Immunotherapy of Cancer Conference, European Lung Cancer Congress, SSO Annual Meeting, SGO Annual Meeting, European Kidney Cancer Association International Meeting, Community Oncology Alliance (COA), ACCC |
|
May 25th |
SSO Annual Meeting, Oncology Nursing Society Annual Congress (ONS), SGO Annual Meeting, ASCO 2020 Pre-Meeting Highlights, COA, NCCN |
2022 ASCO Annual Meeting |
Jun 3rd |
Narratives in Oncology: Profiling oncology leaders, innovators, and pioneers |
2022 ASCO Annual Meeting |
Jun 10th |
ASCO Annual Meeting, AACR Annual Meeting, NCCN Annual Conference |
|
Jun 25th |
ASCO Annual Meeting, AACR Annual Meeting |
Best of ASCO Hollywood |
Jul 10th |
ASCO Annual Meeting, International Conference on Malignant Lymphoma, European Hematology Association Annual Congress (EHA) |
Best of ASCO New Orleans, IASLC World Conference on Lung Cancer |
Jul 25th |
ASCO Annual Meeting, MASCC/ISOO Annual Meeting on Supportive Care in Cancer, EHA |
Best of ASCO DC, |
Aug 10th |
Best of ASCO, Washington, DC, ASCO Annual Meeting, MASCC/ISOO, International Conference on Malignant Lymphoma, EHA |
|
Aug 25th |
Best of ASCO, Hollywood, MASCC/ISOO, International Conference on Malignant Lymphoma, American Head & Neck Society Annual Meeting, Pan Pacific Lymphoma Conference, EHA |
|
Sep 10th |
Best of ASCO, Washington, DC, Best of ASCO, Hollywood, Best of ASCO, New Orleans, American Head & Neck Society Annual Meeting |
ASCO Quality Care Symposium, |
Sep 25th |
Best of ASCO, New Orleans, MASCC/ISOO, Debates and Didactics in Hem/Onc, IASLC (World Lung), |
|
Oct 10th |
IASLC, |
ASTRO, NCCN Hematologic Malignancies Congress, JADPRO Live |
Oct 25th |
ASCO Quality Care Symposium, IASLC, Society of Hematology-Oncology (SOHO), International Workshop on Chronic Lymphocytic Leukemia (IwCLL), |
Society for Immunotherapy of Cancer (SITC) |
Nov 10th |
NCCN Hematologic Malignancies Congress, ASCO Quality Care Symposium, ESMO, IASLC (World Lung), IwCLL, |
|
Nov 25th |
NCCN Hematologic Malignancies Congress, ESMO, IASLC (World Lung), ASTRO Annual Meeting, Society of Integrative Oncology (SIO) Annual Meeting |
ASH Annual Meeting, SABCS |
Dec 10th |
ASTRO Annual Meeting, ESMO, JADPRO Live, Chemotherapy Foundation Symposium |
|
Dec 25th |
ASH, Society for NeuroOncology Annual Meeting, Annual Meeting of the Society of Urologic Oncology (SUO), SITC 35th Annual Conference, SABCS |
ASCO 2023 Gastrointestinal Cancers Symposium, ASCO 2023 Genitourinary Cancers Symposium |
*Subject to change. If a meeting is virtual only, no bonus distribution will be available
Disease-Specific Editorial Focus Months |
|
---|---|
Feb |
World Cancer Day (February 4), National Cancer Prevention Month, Triple Negative Breast Cancer Day |
Mar |
Colorectal Cancer, Renal Cell Carcinoma, Multiple Myeloma |
May |
Melanoma |
Jun |
Survivorship |
Jul |
Sarcoma Awareness |
Sep |
Prostate Cancer, Gynecologic Cancers, Leukemia/Lymphoma, Childhood Cancers |
Oct |
Breast Cancer |
Nov |
Lung Cancer, Pancreatic Cancer |
Frequency |
King-pg |
3/4-pg |
Island 1/2-Pg |
1/4-page |
---|---|---|---|---|
1× |
$6,275 |
$5,820 |
$4,870 |
$3,395 |
6× |
$6,210 |
$5,785 |
$4,825 |
$3,375 |
12× |
$6,160 |
$5,735 |
$4,785 |
$3,345 |
24× |
$6,090 |
$5,695 |
$4,740 |
$3,330 |
36× |
$6,035 |
$5,650 |
$4,690 |
$3,305 |
48× |
$5,970 |
$5,610 |
$4,650 |
$3,290 |
60× |
$5,930 |
$5,570 |
$4,615 |
$3,260 |
72× |
$5,885 |
$5,520 |
$4,570 |
$3,240 |
96× |
$5,860 |
$5,475 |
$4,520 |
$3,225 |
120× |
$5,815 |
$5,435 |
$4,485 |
$3,195 |
144× |
$5,780 |
$5,390 |
$4,435 |
$3,175 |
170× |
$5,730 |
$5,350 |
$4,390 |
$3,155 |
194× |
$5,680 |
$5,310 |
$4,350 |
$3,130 |
216× |
$5,650 |
$5,260 |
$4,315 |
$3,115 |
242× |
$5,600 |
$5,215 |
$4,265 |
$3,095 |
268× |
$5,565 |
$5,185 |
$4,230 |
$3,075 |
304× |
$5,510 |
$5,130 |
$4,180 |
$3,055 |
340× |
$5,435 |
$5,050 |
$4,095 |
$2,995 |
376× |
$5,380 |
$5,000 |
$4,055 |
$2,960 |
Frequency |
King-pg |
3/4-pg |
Island 1/2-Pg |
1/4-pg |
---|---|---|---|---|
1× |
$8,800 |
$8,345 |
$7,395 |
$5,920 |
6× |
$8,735 |
$8,310 |
$7,350 |
$5,900 |
12× |
$8,685 |
$8,260 |
$7,310 |
$5,870 |
24× |
$8,615 |
$8,220 |
$7,265 |
$5,855 |
36× |
$8,560 |
$8,175 |
$7,215 |
$5,830 |
48× |
$8,495 |
$8,135 |
$7,175 |
$5,815 |
60× |
$8,455 |
$8,095 |
$7,140 |
$5,785 |
72× |
$8,410 |
$8,045 |
$7,095 |
$5,765 |
96× |
$8,385 |
$8,000 |
$7,045 |
$5,750 |
120× |
$8,340 |
$7,960 |
$7,010 |
$5,720 |
144× |
$8,305 |
$7,915 |
$6,960 |
$5,700 |
170× |
$8,255 |
$7,875 |
$6,915 |
$5,680 |
194× |
$8,205 |
$7,835 |
$6,875 |
$5,655 |
216× |
$8,175 |
$7,785 |
$6,840 |
$5,640 |
242× |
$8,125 |
$7,740 |
$6,790 |
$5,620 |
268× |
$8,090 |
$7,710 |
$6,755 |
$5,600 |
304× |
$8,035 |
$7,655 |
$6,705 |
$5,580 |
340× |
$7,960 |
$7,575 |
$6,620 |
$5,520 |
376× |
$7,905 |
$7,525 |
$6,580 |
$5,485 |
Frequency |
2-page |
4-page |
6-page |
8-page |
---|---|---|---|---|
1× |
$10,465 |
$20,330 |
$30,250 |
$40,045 |
6× |
$10,375 |
$20,150 |
$29,980 |
$39,685 |
12× |
$10,295 |
$19,990 |
$29,740 |
$39,365 |
24× |
$10,205 |
$19,810 |
$29,470 |
$39,005 |
36× |
$10,105 |
$19,610 |
$29,170 |
$38,605 |
48× |
$10,025 |
$19,450 |
$28,930 |
$38,285 |
60× |
$9,955 |
$19,310 |
$28,720 |
$38,005 |
72× |
$9,865 |
$19,130 |
$28,450 |
$37,645 |
96× |
$9,765 |
$18,930 |
$28,150 |
$37,245 |
120× |
$9,695 |
$18,790 |
$27,940 |
$36,965 |
144× |
$9,595 |
$18,590 |
$27,640 |
$36,565 |
170× |
$9,505 |
$18,410 |
$27,370 |
$36,205 |
194× |
$9,425 |
$18,250 |
$27,130 |
$35,885 |
216× |
$9,355 |
$18,110 |
$26,920 |
$35,605 |
242× |
$9,255 |
$17,910 |
$26,620 |
$35,205 |
268× |
$9,185 |
$17,770 |
$26,410 |
$34,925 |
304× |
$9,085 |
$17,570 |
$26,110 |
$34,525 |
340× |
$8,915 |
$17,230 |
$25,600 |
$33,845 |
376× |
$8,835 |
$17,070 |
$25,360 |
$33,525 |
Frequency |
2-page |
4-page |
6-page |
8-page |
---|---|---|---|---|
1× |
$13,275 |
$25,950 |
$38,680 |
$51,285 |
6× |
$13,145 |
$25,690 |
$38,290 |
$50,765 |
12× |
$13,045 |
$25,490 |
$37,990 |
$50,365 |
24× |
$12,905 |
$25,210 |
$37,570 |
$49,805 |
36× |
$12,795 |
$24,990 |
$37,240 |
$49,365 |
48× |
$12,665 |
$24,730 |
$36,850 |
$48,845 |
60× |
$12,585 |
$24,570 |
$36,610 |
$48,525 |
72× |
$12,495 |
$24,390 |
$36,340 |
$48,165 |
96× |
$12,445 |
$24,290 |
$36,190 |
$47,965 |
120× |
$12,355 |
$24,110 |
$35,920 |
$47,605 |
144× |
$12,285 |
$23,970 |
$35,710 |
$47,325 |
170× |
$12,185 |
$23,770 |
$35,410 |
$46,925 |
194× |
$12,085 |
$23,570 |
$35,110 |
$46,525 |
216× |
$12,025 |
$23,450 |
$34,930 |
$46,285 |
242× |
$11,925 |
$23,520 |
$34,630 |
$45,885 |
268× |
$11,855 |
$23,110 |
$34,420 |
$45,605 |
304× |
$11,745 |
$22,890 |
$34,090 |
$45,165 |
340× |
$11,595 |
$22,590 |
$33,640 |
$44,565 |
376× |
$11,485 |
$22,370 |
$33,310 |
$44,125 |
Position |
Charge |
---|---|
Fourth cover |
50% over B&W rate |
Third cover |
15% over B&W rate |
First ad |
25% over B&W rate |
Center spread |
25% over B&W rate |
Consecutive right-hand pages |
20%* over B&W rate |
All other guaranteed positioning |
10% over B&W rate |
*On 2nd and 3rd pages, up to 3 pages. For addt'l pages contact Publisher.
Color |
Charge |
---|---|
Four color |
$2,525 |
Two color standard |
$845 |
Two color matched |
$1,220 |
Bleed: No charge
Frequency |
2 page supplied |
2 page plus PI |
---|---|---|
1× |
$31,395 |
$37,395 |
6× |
$31,125 |
$37,125 |
12× |
$30,885 |
$36,885 |
24× |
$30,615 |
$36,615 |
36× |
$30,315 |
$36,315 |
48× |
$30,075 |
$36,075 |
60× |
$29,865 |
$35,865 |
72× |
$29,595 |
$35,595 |
96× |
$29,295 |
$35,295 |
120× |
$29,085 |
$35,085 |
144× |
$28,785 |
$34,785 |
170× |
$28,515 |
$34,515 |
194× |
$28,275 |
$34,275 |
216× |
$28,065 |
$34,065 |
242× |
$27,765 |
$33,765 |
268× |
$27,555 |
$33,555 |
304× |
$27,255 |
$33,255 |
340× |
$26,745 |
$32,745 |
376× |
$26,505 |
$32,505 |
Advertisements available in oncology meeting section.
Net pricing |
1× |
3× |
6× |
---|---|---|---|
1/4 pg 4c |
$3,850 |
$3,655 |
$3,470 |
1/8 pg 4c |
$2,785 |
$2,625 |
$2,470 |
Harborside can convert inserts of 4 pages or larger to king-sized ad pages at no cost. The converted ad will be billed at the king-sized B&W page rate times the number of pages. Digital file required. For additional information, please contact Norman W. Virtue at 631-935-7682 or nvirtue@hbside.com.
BRCs are billed at half of a 2-page island-sized insert rate page with a minimum island half-page ad opposite. A sample of the BRC and paper must be submitted to the publisher for approval two weeks before closing date.
Harborside will match any client list to The ASCO Post's circulation. The first 2 list matches are free, charge of $2,000 applies to all subsequent matches. If the client chooses to advertise to the selected audience through a demo insert, the appropriate demo charge will apply, and the initial list match fee will be waived. Maximum of 2 list matches per year per brand.
Billing is based on the earned insert rate times the percentage of circulation, with a minimum of 50% of the total circulation, plus a noncommissionable production charge of $2,500. For a run-of-book split-run charge, please contact the publisher.
Note: there is a maximum of 4 split-runs per issue
If multiple sized ad units are placed within the first 5 insertions, the cost of the 6th ad unit will be determined by the average dollar amount spent per issue. This amount will be credited toward the 6th insertion in a series.
Advertisers in ASCO Publications: The ASCO® Post, Journal of Clinical Oncology (JCO), and JCO Oncology Practice (JCO OP) combine for pages to earn the frequency rate in The ASCO® Post as well as in all the ASCO journal publications. Space purchased by a parent company and subsidiaries is combined in calculating the earned rate. When the number of insertions is greater or less than indicated by the contract, rates are adjusted accordingly. Please contact Harborside for details. Frequency will be determined by the total number of pages placed in these publications during a calendar year.
*Guaranteed frequency is based on the number of pages placed between July 2020-June 2021
Advertise three or more prescribing information (PI) pages for a single ad for a brand and receive a 50% discount on the B&W page rate beginning on the third PI page. Multi-journal discount is not eligible for discounted PI pages.
Each individual product advertising in ASCO’s Journal of Clinical Oncology (JCO) AND/OR ASCO’s JCO Oncology Practice (JCO OP) during the same month it advertises in The ASCO® Post will receive a $500 per page discount in The ASCO® Post. Discount is based on the matching number of pages in The ASCO® Post and JCO or JCO OP in a given month.*
*Discount is only applied to fully priced ad pages
Placement of Advertising: Interspersed within articles. Placement location is at the discretion of Harborside.
All advertising is subject to approval of the Editor-in-Chief, publisher, and ASCO. New advertisements are to be received by the publisher at least two weeks before the closing date. Please email all ad proofs to Norman W. Virtue at nvirtue@hbside.com. The publisher reserves the right to label any advertisement as such for any ads that contain significant editorial content or that look like editorial pages.
The advertiser and advertising agency accept and assume liability for all content (including text, representations, illustrations, opinions, and facts) of advertisements and their compliance with all applicable laws and regulations and also assume responsibility for any claims made against the publisher or ASCO arising from or related to such advertisements.
Advertiser and advertising agency recognize and accept that the following language appears within the publication: “All statements, including product claims, are those of the person or organization making the statement or claim. Neither the publisher nor ASCO adopts any such statement or claim as its own, and any such statement or claim does not necessarily reflect the opinion of the publisher or ASCO.”
In the event that legal action or a claim is made against the publisher or ASCO arising from or related to such advertisements, the advertiser and advertising agency agree to fully defend, indemnify, and hold harmless the publisher and ASCO and to pay any judgment, expenses, and legal fees incurred by the publisher or ASCO as a result of said legal action or claim.
In addition, the publisher reserves the right to reject or discontinue any advertising for any reason. This right shall not be deemed to have been waived by acceptance or actual use of any advertising matter.
The publisher reserves the right to label any advertisement as such for any ads that contain significant editorial content or that look like text pages. The publisher is not liable for delays in delivery and/or nondelivery due to any condition beyond the control of the publisher affecting production or delivery in any manner.
The publisher reserves the right to reject any advertising that it believes is not in keeping with the publication’s standards.
Advertiser and advertising agency agree to indemnify, defend, and hold harmless the publisher from any and all liability for content (including text, illustrations, representatives, sketches, maps, trademarks, labels, or other copyrighted matter) of advertisement printed or the unauthorized use of any person’s name or photography arising from the publisher’s reproduction and publishing of such advertisements pursuant to the advertiser’s or agency’s order.
Earned Frequency: Harborside will determine the number of pages and fractions of pages placed in The ASCO Post during the year.
Combined Frequency: Harborside will combine all advertising insertions of a parent company and its subsidiaries to determine the earned rate.
Commercial article reprints and electronic reprints (ePrints) are available.
Please contact Amy Schriver, Manager, Content Solutions, The Sheridan Press.
800-635-7181 Ext. 8184; Amy.schriver@sheridan.com
Contact Infocus Marketing Inc. List Manager, 4245 Sigler Road, Warrenton, VA 20187; 540-428-3251; or www.infocusmarketing.com
Supplements, special issues, newsletters, patient education material, and additional customized opportunities available.
Fifteen percent (15%) of gross billings on space, color, cover, and preferred position charges. Additional production charges are noncommissionable.
SWOP standards apply. Submit only high-resolution CMYK PDF formatted files. Convert all spot colors to CMYK. All fonts and images must be embedded. Files should indicate trim and bleed.
Contact the Production Manager at nvirtue@hbside.com for additional specifications and production questions.
Island
Bleed: 7.75" × 10.5"
Trim: 7.5" × 10.00"
Live: 7.00" × 9.00"
Island Spread
Bleed: 15.5" × 10.5"
Trim: 15.00" × 10.00"
Live: 14.5" × 9.25" with a 0.75" gutter down the middle.
King
Bleed: 10.75" × 14.00"
Trim: 10.5" × 13.75"
Live: 9.5" × 12.75"
King Spread
Bleed: 21.25" × 14.00"
Trim: 21" × 13.75"
Live: 20" × 12.75" with a 0.75" gutter down the middle.
Half-Page Vertical
Bleed: 5.375" × 14.00"
Trim: 5.125" × 13.75"
Live: 4.625" × 12.75"
Half-Page Horizontal
Bleed: 10.75" × 7.00"
Trim: 10.5" × 6.75"
Live: 9.5" × 5.75"
Half-Page Horizontal Spread
Bleed: 21.25" × 7.00"
Trim: 21" × 6.75"
Live: 20" × 5.75" with a 0.75" inch gutter down the middle.
Quarter-Page Rectangle
Bleed: 5.375" × 7.00"
Trim: 5.125" × 6.75"
Live: 4.625" × 5.75"
Quarter-Page Vertical
Bleed: 3.045" × 14.00"
Trim: 2.75" × 13.75"
Live: 2.25" × 12.75"
3/4-Page Horizontal
Bleed: 10.75" × 10.75"
Trim: 10.5" × 10.5"
Live: 9.5" × 10.00"
3/4-Page Vertical
Bleed: 7.825" × 14.00"
Trim: 7.575" × 13.75"
Live: 7.125" × 12.74"
2 mockups must be provided for proposed piece. Mockups are needed to head off potential problems during binding and allow Publisher to provide feedback on how to correct any problems prior to delivery. Once samples are received, it will also be determined if additional postage and binding charges will be necessary. For a simple two-sided piece, a mockup is not necessary. All other configurations require mockups, which are due 6 weeks before due date to printer.
Norman Virtue, Harborside, 244 Hillside Ave, Valley Stream, NY, 11580
Send PDF file of the creative for preapproval by ASCO to: nvirtue@hbside.com
Royle Printing
Jenny Turk - CSR
745 S Bird Street, Sun Prairie, WI 53590
All inserts must be palletized
For additional information, contact Royle Printing: (608) 837-5161 ext. 433 or email: receiving@royle.com
The ASCO Post accepts cover tip variations–cover tip with PI affixed to back, pocket cover tips with PI enclosed, etc. It is recommended that there be 2" clearance between the edge of the PI and the gutter edge of the cover tip.
Files are held for one year and then destroyed, unless instructed otherwise in writing. Unused inserts will be destroyed one month after issue mails.
Email: hspadorders@hbside.com
Insertion order should include an ad code or unique identifier to help properly identify the corresponding ad material.
email: hspadmats@hbside.com
FTP: prodweb2.hbrsd.com
Username: hspsales
password: Connect#9
We recommend using a secure file transfer protocol. Such as SFTP FileZilla
Norman W. Virtue, The ASCO Post,
244 Hillside Ave
Valley Stream, NY 11580
Tel: 631-935-7682, Fax: 631-692-0805
Norman Virtue
244 Hillside Ave
Valley Stream, NY 11580
Issue Date |
Insertion Order Due |
Ad Material Due |
Inserts Due |
---|---|---|---|
Jan 25th |
12/23/21 |
1/5/22 |
1/10/22 |
Feb 10th |
1/7/22 |
1/14/22 |
1/21/22 |
Feb 25th |
1/24/22 |
1/31/22 |
2/7/22 |
Mar 10th |
2/7/22 |
2/14/22 |
2/21/22 |
Mar 25th |
2/24/22 |
3/3/22 |
3/10/22 |
Apr 10th |
3/9/22 |
3/16/22 |
3/23/22 |
Apr 25th |
3/24/22 |
3/31/22 |
4/7/22 |
May 10th |
4/11/22 |
4/18/22 |
4/25/22 |
May 25th |
4/20/22 |
4/27/22 |
5/4/22 |
Jun 3rd |
4/22/22 |
4/29/22 |
5/6/22 |
Jun 10th |
5/9/22 |
5/16/22 |
5/23/22 |
Jun 25th |
5/23/22 |
5/27/22 |
6/6/22 |
Jul 10th |
6/10/22 |
6/17/22 |
6/24/22 |
Jul 25th |
6/24/22 |
7/1/22 |
7/8/22 |
Aug 10th |
7/8/22 |
7/15/22 |
7/22/22 |
Aug 25th |
7/25/22 |
8/1/22 |
8/8/22 |
Sep 10th |
8/10/22 |
8/17/22 |
8/24/22 |
Sep 25th |
8/25/22 |
9/1/22 |
9/8/22 |
Oct 10th |
9/9/22 |
9/16/22 |
9/23/22 |
Oct 25th |
9/23/22 |
9/30/22 |
10/7/22 |
Nov 10th |
10/10/22 |
10/17/22 |
10/24/22 |
Nov 25th |
10/24/22 |
10/31/22 |
11/7/22 |
Dec 10th |
11/10/22 |
11/17/22 |
11/23/22 |
Dec 25th |
11/23/22 |
11/30/22 |
12/7/22 |
*On mobile size displays the 728 × 90 ad location is replaced with a 320 × 50 banner ad.
ASCOPost.com 2021 U.S. Average Stats* |
|
---|---|
Sessions Per Month |
143,300 |
Users Per Month |
101,000 |
Pageviews Per Month |
179,950 |
Time on Site |
0:16:20 |
Impressions Per Month |
552,795 |
*Based on US average stats Jan 2021-June 2021 Google Analytics, Google Ad Manger
ASCOPost.com 2021 Average Stats* |
EX-US |
---|---|
Sessions per Month |
106,229 |
Users per Month |
72,400 |
Time on Site |
0:03:51 |
Pageviews Per Month |
136,000 |
Impressions Per Month |
417,000 |
*Based on Ex-US average stats Jan 2021-June 2021 Google Analytics, Google Ad Manger
For custom quotes by country, contact your representative.
For rates and availability please contact your representative for details.
Available with ASCO Publications Network
All ASCO publication website impressions are now exclusively available through multi channel high SOV tumor specific segments.
Each segment includes ASCO publication e-newsletters, ROS website banners, and targeted banners to self identified ASCO members and/or high readers of specific content and contextual impressions.
Business Intelligence Report available for qualifying advertisers
Circulation* |
USA |
EX-US |
---|---|---|
Total Distribution (Average) |
19,500 |
9,000 |
ASCO Members |
15,000 |
8,300 |
Requesters |
3,300** |
1,800 |
*Based on average. Subject to change.
**includes 1,500 APHSO members
Issue Date |
Email Date |
Ad Due Date |
Commitment Date |
---|---|---|---|
01/25/22 |
01/25/22 |
01/18/22 |
01/11/22 |
02/10/22 |
02/10/22 |
02/03/22 |
01/27/22 |
02/25/22 |
02/25/22 |
02/18/22 |
02/11/22 |
03/10/22 |
03/10/22 |
03/03/22 |
02/24/22 |
03/25/22 |
03/25/22 |
03/18/22 |
03/11/22 |
04/10/22 |
04/11/22 |
04/04/22 |
03/28/22 |
04/25/22 |
04/25/22 |
04/18/22 |
04/11/22 |
05/10/22 |
05/10/22 |
05/03/22 |
04/26/22 |
05/25/22 |
05/25/22 |
05/18/22 |
05/11/22 |
06/10/22 |
06/10/22 |
06/03/22 |
05/27/22 |
06/25/22 |
06/24/22 |
06/17/22 |
06/10/22 |
07/10/22 |
07/11/22 |
07/04/22 |
06/27/22 |
07/25/22 |
07/25/22 |
07/18/22 |
07/11/22 |
08/10/22 |
08/10/22 |
08/03/22 |
07/27/22 |
08/25/22 |
08/25/22 |
08/18/22 |
08/11/22 |
09/10/22 |
09/09/22 |
09/02/22 |
08/26/22 |
09/25/22 |
09/26/22 |
09/19/22 |
09/12/22 |
10/10/22 |
10/10/22 |
10/03/22 |
09/26/22 |
10/25/22 |
10/25/22 |
10/18/22 |
10/11/22 |
11/10/22 |
11/10/22 |
11/03/22 |
10/27/22 |
11/25/22 |
11/23/22 |
11/16/22 |
11/09/22 |
12/10/22 |
12/09/22 |
12/02/22 |
11/25/22 |
12/25/21 |
12/22/22 |
12/15/22 |
12/08/22 |
2021 Average Stats* |
USA |
EX-US |
---|---|---|
Open Rate |
36.88% |
37.00% |
Opens |
7,300 |
4,780 |
Email Click Through Rate |
17.97% |
22.24% |
*Based on Average Stats Jan-Sep 2021
Send all digital material to digitalads@hbside.com
Available Topics |
List Sizes |
---|---|
Breast Cancer |
6,500 |
Colorectal Cancer |
1,300 |
Gastrointestinal Cancer |
4,500 |
Genitourinary Cancer |
3,000 |
Hematology |
7,500 |
Leukemia |
2,500 |
Lung Cancer |
4,700 |
Lymphoma |
2,500 |
Multiple Myeloma |
1,500 |
Skin Cancer |
1,700 |
For rates and availability, please contact your representative for details.
Email Distribution* |
USA |
EX-US |
---|---|---|
Total Distribution (Average) |
19,500 |
9,000 |
ASCO Members |
14,500 |
7,800 |
Requesters |
3,000 |
2,500 |
Advance Practitioners in Oncology (APSHO) |
1,500 |
N/A |
*Based on average. Subject to change.
Issued: Daily (On weekdays, as well as some weekend meeting dates)
2021 Average Stats* |
USA |
EX-US |
---|---|---|
Open Rate |
36.84% |
47.05% |
Opens |
7,600 |
4,900 |
E-mail Click-Through Rate |
14% |
18.5% |
*Based on Average Stats Jan-Oct 2021
In an independently audited and tabulated email survey of all ASCO members conducted in August 2015 and based on 421 US respondents
Major oncology meeting dates available at a premium
Send all digital material to digitalads@hbside.com
Digital | ||||||
---|---|---|---|---|---|---|
Conference | Specialty Audience | Sent With Issue | Print Circulation | Production Deadline | E-TOC #1* | E-TOC #2** |
American Society of Hematology** | Hematology | February 25th | 14,000 | 1/8/21 | 19,500 | 8,000 |
San Antonio Breast Cancer Symposium | Breast Cancer | March 10th | 6,993 | 1/22/21 | 19,500 | 7,400 |
IASLC World Conference on Lung Cancer | Lung | September 25th | 5,979 | 8/24/21 | 19,500 | 5,800 |
ESMO | Med Oncs and Hem Oncs | October 25th | 14,000 | 9/24/21 | 19,500 | 8,600 |
Note: Bonus distribution (approx 100 copies) may be available at other meetings of interest.
Other meetings available include SOHO, SGO, ASTRO and others.
*sent to The ASCO Post E-TOC circulation
**As part of the ASH Annual Packages
Package |
Price |
eTOCs |
Website |
Cost |
---|---|---|---|---|
SOV #1 |
Cover Tip + TOC |
50% SOV on Email #1 + Email #2 |
50% SOV of impressions |
$60,000 net |
SOV #2 |
Cover 2 + Cover 4 |
50% SOV on Email #1 + Email #2 |
50% SOV of impressions |
$60,000 net |
See ad specs in the Almanacs section below
A round-up of news items specific to a disease site and/or tumor type, including important clinical trial data, emerging therapies, and expert perspectives. The ASCO Post Almanacs are distributed via mail and emailed to a self-identified target audience plus Med Onc and/or Hem Onc readers of The ASCO Post.
50% SOV includes print and digital components.
A-size
Bleed: 8.375" × 11.125"
Trim: 8.125" × 10.875"
Safety: 7.625" × 10.375"
A-size spread
Bleed: 16.5" × 11.125"
Trim: 16.25" × 10.875"
Safety: 15.75" × 10.375"
with a 0.5" safety down the middle
Topic areas available* include: |
|
---|---|
April |
Head and Neck Cancers |
May |
GU Cancers, Melanoma |
June |
Supportive Care |
July |
Lung Cancers |
August |
Sarcoma |
September |
CNS Malignancies, GI Cancers, GYN Cancers, Prostate Cancers |
October |
Breast Cancer |
November |
Hematologic Malignancies |
*Issue dates are flexible, please contact your representative for more information.
Package |
Price |
eTOCs |
Website |
Cost |
---|---|---|---|---|
SOV #1 |
Cover Tip + TOC |
50% SOV on Email #1 + Email #2 |
50% SOV of impressions |
$60,000 net |
SOV #2 |
Cover 2 + Cover 4 |
50% SOV on Email #1 + Email #2 |
50% SOV of impressions |
$60,000 net |
For more information, contact your sales representative or email us at apninfo@hbside.com
Timing: Up to 12 month opportunity
SOV Per Roundtable: 50%-100%
Guarantees: Page Visits
Rate type: CPE
Date |
Topic |
---|---|
February |
Hematology |
April |
Lung |
June |
Genitourinary |
August |
Immunotherapy |
October |
Gastrointestinal |
December |
Breast |
*Issue dates are flexible, please contact your representative for more information.
Journal Marks offer advertisers excellent visibility by providing The ASCO Post readers a removable tab that carries your message.
Rate: $25,950
Rate includes printing, and is for a 2 pg ad plus the removable tab. For larger ad units, please contact Harborside for a custom quote.
Artwork, design, and content must be approved prior to printing.
Norman W. Virtue (nvirtue@hbside.com)
May-July
*Digital-only option available upon request
25% SOV
Oct-Dec OR Dec-Feb
*Digital-only option available upon request
25% SOV
Specification |
Website |
e-TOC/The Asco Post Evening News |
---|---|---|
Accepted ad sizes |
Leaderboard (728 × 90) Medium Rectangle (300 × 250) Mobile (320/300 x 50) |
Leaderboard (728 × 90) Medium Rectangle (300 × 250) |
Ad expansion sizes |
Leaderboard (728 × 315) (Expands down) Medium Rectangle (600 × 250) (Expands left) |
N/A |
Ad expansion notes |
Ad must require user click initiation for expansion. Expanded ad must include |
N/A |
Ad formats |
JPG, GIF, HTML5, Javascript, |
JPG, GIF, animated GIF |
Maximum initial file size |
160K |
60K |
Rich media file size |
200K |
N/A |
Animation time |
15 seconds, 3 frames, 3 loops |
15 seconds, 3 frames, 3 loops** |
Frames per second (FPS) |
24 FPS |
24 FPS |
Border |
All ads with white or partially white |
All ads with white or partially white background must use a 1-pixel dark color border |
Maximum Ad Resource Requests *** |
15 |
N/A |
All ad creative is due one week prior to live date and is subject to approval by ASCO. Email creative must be finalized no later than 72 hours prior to deployment. HTML5 ads must be provided as soon as possible for testing purposes.
All ad creative is subject to approval from the American Society of Clinical Oncology. For times when the user’s browser does not support creative functionality (i.e. Flash™, HTML5), provide a standard image file.
**Animated .gif files should resolve into a comprehensive static image.
***Resource request limits include any tracking scripts that the agency/advertiser may be utilizing in conjunction with their campaign.
‡ Please provide alternative text (up to 64 characters including spaces).
Interactive ads will allow for unlimited file load after user-initiated interaction. User initiation is the willful act of a user to engage with an ad. Users may interact by clicking on the ad.
File weight calculation: All files for the ad, including supporting files and agency supplied tracking scripts, must be included as part of the maximum file weight calculation for all file limits load.
For E-TOC Images, please provide alternative text (up to 64 characters
including spaces).
Keyword Blocking: If a keyword blocker is being utilized, all keywords need to be included within the IO in advance of acceptance. Failure to do so, will result in advertiser being billed for blocked impressions.
HTML5 Best Practice Notes:
HTML5 ads are like mini web pages. You can improve initial display by following a few guidelines:
Ads must not load more than 15 supporting files, including any agency supplied tracking scripts.
Use well-distributed, cached libraries to provide supporting files instead of providing them with the ad.
Check device and bandwidth and tailor supporting files and other elements to the environment and experience.
Harborside utilizes a number of viewability/ivt analyzation tools for comprehensive data on advertising CAMPAIGNS. If there is a 10% difference between third-party reporting, a conversation ensues between client and Harborside.
† No Advertising shall include any pixels, tags, Flash containers, or any other type of information collection software code (i.e. any such pixel, tag, code or device commonly referred to as a “Pixel”), nor place any beacons, cookies, or other information collection devices on the browsers of users unless expressly approved in writing by Harborside. If Harborside approves the inclusion of a Pixel in an advertisement, then unless and only to the extent that such approval contains an express exception, (i) Advertiser may not use such Pixel to collect any personally-identifiable information (PII) with respect to any The ASCO Post user, (ii) no such Pixel can be flash or object based, (iii) No cookies may be placed on a user’s system, (iv) Advertiser will not link any non-PII that it collects to any PII that it may have from any other source and (v) Advertiser will not update any existing profile or create any profile in its database based on any data collected on the The ASCO Post site, including the fact that someone is a The ASCO Post user or any information derived from the information in the referring URL.
We cannot honor viewability related campaign goals if ads are supplied that do not meet the specifications supplied in the grid above.
IVT-related campaign requirements cannot be honored if logs including IP addresses and timestamps are not supplied of suspected IVT-generated impressions for verification. These logs also enable us to ensure that we filter out future IVT visitations from these addresses if deemed valid. Harborside will supply a report back of any IVT traffic deemed valid along with supporting evidence.
The publisher is not liable for delays in delivery and/or nondelivery in the event of an Act of God, action by any governmental or quasigovernmental entity, fire, flood, insurrection, riot, explosion, embargo, strikes (whether legal or illegal), labor or material shortage, transportation interruption of any kind, work slow-down, or any condition beyond the control of the publisher affecting production or delivery in any manner.
Insertion Order and Copy Regulations: Insertion instructions shall be supplied for every advertisement and shall clearly state the following information: name of publication, name of advertiser, date to be inserted, size of advertisement, identification of advertisement (proof of ad to be furnished if possible), plus any special instruction such as bleed and color.
Cancellation of space order forfeits the right to position protection.
The publisher’s liability for any error will not exceed the charge for the advertisement in question.
The publisher assumes no liability if for any reason it becomes necessary to omit an advertisement.
When change of copy, covered by an uncancelled insertion order, is not received by the closing date, copy run in the previous issue will be inserted.
Requests for specified position at ROB rates are given consideration, but no guarantee is made unless the position premium has been agreed to in the contract.
The publisher reserves the right to hold advertiser and/or its advertising agency jointly and severally liable for such monies as are due and payable to the publisher.
In the event that an advertiser is owed a credit as a result of adjustment of frequency rates, the publisher will provide credit only on future advertisements.
Payment Terms: Net 30 days of invoice date. Pre-payment discounts are available, contact publisher for more details.
Payment for New Advertisers: All new advertisers are required to prepay until credit and/or reference checks are completed. Once approved, Harborside payment terms are net 30 days. Contact the Harborside Finance Team at accounting@hbside.com for more details.
Viewability: 70% Viewability is current industry standard. Ads taking more than 3 seconds to load will not qualify for viewability makegoods. If there is a 10% difference between third-party reporting, a conversation ensues between client and Harborside.
Print Cancellations: Cancellations in advertising by the advertiser or its agency may not be made after the closing date for the publication unless otherwise agreed to by both parties in writing.
Premium Position, Cover Tip, and Outsert Cancellations: Must be prior to 60 days of the published closing date. After the published closing date, any premium position, cover tip, or outsert is non-cancelable, and full payment is due.
Please see page 5 for list of premium positions.
Digital Cancellations for e-TOC’s and Evening News:
Advertiser may cancel the I/O as follows:
Cost per Thousand (CPM) Placements:
Cost per Engagement (CPE) Placements:
For Flat-Fee or Fixed Placements (e-TOC’s and Evening News)
For Website or CPM Placements
Editor-in-Chief
James O. Armitage, MD, FASCO
President
Lori Pierce, MD, FASTRO, FASCO
President-Elect
Everett E. Vokes, MD, FASCO
Chief Executive Officer
Clifford A. Hudis, MD, FACP, FASCO
Chairman
John A. Gentile, Jr.
jgentile@hbside.com
President
Anthony Cutrone
acutrone@hbside.com
Executive Vice President
Conor Lynch
clynch@hbside.com
VP, Director of Advertising Sales
Leslie Dubin
631-935-7660
ldubin@hbside.com
VP, Senior Accounts Manager
Nick Vroom
917-538-0699
nvroom@hbside.com
National Accounts Representative
Shannon Meserve
631-935-7651
smeserve@hbside.com
Production Manager
Norman W. Virtue
631-935-7682
nvirtue@hbside.com
SVP, Director of Sales
David Horowitz
631-935-7652
dhorowitz@hbside.com
Advertising Sales Coordinator
Natalie King
631-935-7695
nking@hbside.com
Ad Operations Group
digitalads@hbside.com